Neutrophils News and Research

RSS

Phase II clinical trial results reveal positive effects of omacetaxine against CML

Results from a phase II clinical trial indicate a novel drug may provide a treatment option for chronic myeloid leukemia (CML) patients who do not respond to current therapies, researchers from The University of Texas M. D. Anderson Cancer Center report today at the 51st Annual Meeting of the American Society of Hematology.

8 Dec 2009

Interim data from Celator Pharmaceuticals' CPX-351 trial presented at the ASH meeting

Celator Pharmaceuticals today announced that interim safety and efficacy data from its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin therapy ("7+3") in patients 60-75 years of age with untreated acute myeloid leukemia (AML) were presented at the 51st American Society of Hematology (ASH) Annual Meeting in New Orleans, Louisiana (ASH Abstract # 1033).

7 Dec 2009

New treatment options for leukemia and myeloproliferative disorders introduced

Leukemia and myeloproliferative disorders are serious and often deadly blood cancers. Research presented today at the 51st Annual Meeting of the American Society of Hematology introduces potential new treatment options and improved diagnostic methods for patients suffering from acute promyelocytic leukemia, chronic myeloid leukemia, infant acute lymphoblastic leukemia, and myelofibrosis that are based on a better understanding of the underlying genetic causes of these conditions.

6 Dec 2009

Teva Pharmaceutical Industries submits a BLA for its G-CSF XM02

Teva Pharmaceutical Industries Ltd., today announced the submission of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for XM02, a granulocyte colony-stimulating factor (G-CSF) for the reduction in the duration of severe neutropenia and the incidence of febrile neutropenia in patients treated with established myelosuppressive chemotherapy for cancer.

1 Dec 2009

Interim data from Schering-Plough's narlaprevir Phase IIa study

Schering-Plough Corporation reported that interim results from an ongoing Phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent antiviral activity in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1.

3 Nov 2009

BMY and ZGen present Phase 1B results for PEG-Interferon lambda in HCV patients

Bristol-Myers Squibb Company and ZymoGenetics, Inc. today presented final results from a Phase 1b clinical trial of PEG-Interferon lambda administered with ribavirin in relapsed and treatment-naïve hepatitis C virus (HCV) patients.

2 Nov 2009

Triage NGAL Test allows early identification of AKI in ICU patients

According to a new study now available online, and to be published in an upcoming issue of the Journal of Critical Care, bedside testing for a blood biomarker called neutrophil gelatinase-associated lipocalin (NGAL) in patients being admitted to the intensive care unit can help to identify patients at risk for acute kidney injury (AKI).

6 Oct 2009

Fred Hutchinson Cancer Research Center receives 60 research grants totaling nearly $40.4 million

Scientists at Fred Hutchinson Cancer Research Center have been awarded 60 research grants totaling nearly $40.4 million under the American Recovery & Reinvestment Act of 2009. The totals reflect data available as of Oct. 1 and reported by the National Institutes of Health.

6 Oct 2009

Therapeutic target for acute respiratory distress syndrome identified

Research led by Dr. Jay Kolls, Professor and Chairman of Genetics at LSU Health Sciences Center New Orleans, has identified a therapeutic target for acute lung injury resulting in acute respiratory distress syndrome, a highly fatal complication of influenza infection.

30 Sep 2009

Dental plaque increases neutrophil activity in black males

Will neglecting to brush your teeth damage more than just your smile? Can failing to attack dental plaque increase your risk of heart damage?

25 Sep 2009

Tregs to set the pace of recovery after serious lung injury

After more than 50 experiments in mice, medical scientists at Johns Hopkins have mapped out the basic steps taken by a particular set of white blood cells in setting the pace of recovery after serious lung injury.

22 Sep 2009

Research reveals that reactive oxygen inhibition can limit cancer cell invasion

Researchers at the Burnham Institute for Medical Research (Burnham) have discovered that reactive oxygen species, such as superoxide and hydrogen peroxide, play a key role in forming invadopodia, cellular protrusions implicated in cancer cell migration and tumor metastasis.

17 Sep 2009

Insects can be used to test the efficiency of new drugs

Insects, such as some moths and fruit flies, react to microbial infection in the same way as mammals and so can be used to test the efficiency of new drugs, thereby reducing the need for animal testing. Dr Kevin Kavanagh from the National University of Ireland - Maynooth, presented his research findings at the Society for General Microbiology's meeting at Heriot Watt University, Edinburgh, today (8 September).

7 Sep 2009

Psychological therapy for breast cancer patients reduces blood inflammation levels

A psychological intervention for newly diagnosed breast cancer patients with symptoms of depression not only relieves patients' depression but also lowers indicators of inflammation in the blood.

1 Sep 2009

Two human biomarker assays that play a key role in the early detection of kidney damage provide assistance in drug development

Geneuity Clinical Research Services announces the recent validation and use in clinical trials of two human biomarker assays that play a key role in the early detection of kidney damage.

29 Aug 2009

Cost effectiveness study looks at potential value of new genetic test for guiding chemotherapy treatment

For the 29,000 patients in the United States with metastatic colorectal cancer, chemotherapy with irinotecan is a standard treatment that has been shown to improve survival. But for more than one in 10 of these patients, a variation in their DNA means that this treatment could result in a severe reduction in their white blood cell count, leading to a high risk of bacterial infection and possible subsequent death.

27 Jul 2009

Scent soothes stress

Feeling stressed? Then try savoring the scent of lemon, mango, lavender, or other fragrant plants.

26 Jul 2009

'Urine NGAL' gives clues to kidney injury in ICU patients and HIV-related kidney disease

Acute kidney injury (AKI) is a frequent complication in patients in intensive care. A new laboratory test called urine neutrophil gelatinase associated lipocalin (NGAL) helps predict if patients will develop acute kidney injury, reports an upcoming study in the Journal of the American Society of Nephrology (JASN).

26 Jul 2009

Immune cells in the blood inhibit inflammation after a stroke

In acute ischemic stroke, the blood supply to the brain is restricted. Initially, brain cells die from lack of oxygen.

16 Apr 2009

Seroquel XR supplemental NDA recommended for approval

The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) conducted a review of the safety and efficacy of supplemental new drug applications (sNDA) for Seroquel XR (quetiapine fumarate) extended-release tablets proposed for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD).

9 Apr 2009